BioSpace News Archive

Following two late-stage failures, Travere Therapeutics has unveiled the results of two Phase III studies, attempting to regain Filspari’s footing in IgA nephropathy and focal segmental glomerulosclerosis.

Seeking to weather declining sales from its COVID-19 business in the third quarter, Pfizer is laying off approximately 200 employees at its manufacturing facility in Kalamazoo, Michigan.

Although Kodiak Sciences initially scrapped its development of tarcocimab tedromer after late-stage failures, new data has convinced the company to give the eye drug another shot.

After its deal with Tubulis in April 2023, Bristol Myers Squibb is continuing its antibody-drug conjugate buying spree by acquiring an asset from South Korea’s Orum Therapeutics.

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) today reported financial results for the quarter ending September 30, 2023, and updates from the Company’s key pipeline developments, business operations and upcoming milestones.

SI-BONE, Inc., a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, reported financial results for the quarter ended September 30, 2023.

Chemomab Therapeutics Ltd. disclosed that the Company received notice from the Nasdaq Listing Qualifications Department on November 6, 2023 that the Company is not currently in compliance with the $1.00 minimum bid price requirement for continued listing of its American Depositary Shares on the Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550.

Day One Biopharmaceuticals announced its third quarter 2023 financial results and highlighted recent corporate achievements.

NeoGenomics, Inc. (NASDAQ:NEO) (the “Company”), a leading oncology testing services company, today announced its third-quarter results for the period ended September 30, 2023 as compared to September 30, 2022.

Cellectis, a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, provided business updates and financial results for the nine-month period ending September 30, 2023.